Chronic migraine
Drug research and approvals for chronic migraine: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 59 studies of chronic migraine are recruiting on ClinicalTrials.gov, and Health Canada has authorized 15 drug trials for it since 2013.
- Recruiting worldwide: 59
- Trials authorized in Canada: 15
- FDA orphan approvals: 0
- EU medicines: 0
- Laser Acupuncture for Chronic Migraine: Clinical Response, Traditional Chinese Medicine Syndrome Patterns, and Brain…NCT07891585 · Not applicable · Taichung Veterans General Hospital · starts Nov 1, 2026
- Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in MigraineNCT07769255 · Not applicable · Beni-Suef University · starts Sep 1, 2026
- A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic MigraineNCT07729462 · Phase 3 · Pfizer · starts Aug 26, 2026
- A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant MigraineNCT07719608 · Not applicable · Salvia BioElectronics · starts Dec 1, 2026
- EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for MigraineNCT07652034 · Not reported · Cortex Neurovascular · starts Sep 1, 2026
- Study of EVO756 in Adults With MigraineNCT07616128 · Phase 2 · Evommune, Inc. · starts Jul 29, 2026
- The Neuroanatomical and Psychological Correlates of Suggestibility in Patients With Non-Responsive Chronic MigraineNCT07617441 · Not reported · Istituto per la Ricerca e l'Innovazione Biomedica · starts Jul 1, 2026
- Topical Intranasal Anesthetic Block for Reducing the Pain of Botulinum Toxin Injections for Chronic MigraineNCT07571889 · Not applicable · Association of Migraine Disorders · starts Mar 3, 2026
- Ultrasound Guided Infratemporal Sphenopalatine Ganglion Supravoltage Versus Standard Voltage Pulsed Radiofrequency for…NCT07500558 · Not applicable · Minia University · starts Mar 31, 2026
How its trials ended
1,356 ClinicalTrials.gov studies of migraine in general, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 388 whose ending is known, 60% met their primary endpoint, 7% missed it and 32% stopped early.
- Completed, result not reported55741%
- Ongoing26520%
- Met its primary endpoint23417%
- Status unknown14611%
- Stopped: other or unclear725%
- Stopped: enrollment or feasibility302%
- Missed its primary endpoint282%
- Stopped: lack of efficacy111%
- Stopped: sponsor or business decision91%
- Stopped: funding3<1%
- Stopped: safety1<1%
| Sep 10, 2025 | A multicentre, randomised, double-blind, placebo-controlled, dose escalation and dose finding phase II study to evaluate the safety and efficacy of IPN10200 in…IPN10200 | Ipsen | Ongoing |
| Jul 16, 2025 | A phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of xeomin®…Xeomin | Merz Therapeutics GmbH | Ongoing |
| Mar 6, 2025 | A phase 3, multicenter, 12-week, double blind, placebo-controlled study to evaluate the safety and efficacy of atogepant for the preventive treatment of…Atogepant | AbbVie | Ongoing |
| Aug 30, 2023 | A phase III, randomised, double-blind, placebo-controlled, multicentre, parallel-group study with extension phase to evaluate the efficacy and safety of…Dysport (IPN52120) | Ipsen | Ongoing |
| Mar 4, 2022 | Long term, open label (dose blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraineEptinezumab | H. Lundbeck A/S | Ongoing |
| Mar 4, 2022 | Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of iv eptinezumab in adolescents (12-17…Eptinezumab | H. Lundbeck A/S | Ongoing |
| Jan 22, 2021 | A phase 3, multicenter, open-label 156-week extension study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine…Atogepant | AbbVie | Closed |
| Nov 10, 2020 | A multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing the efficacy, safety, and tolerability of subcutaneous…Ajovy | Teva Pharmaceutical Industries | Ongoing |
| Nov 9, 2020 | A multicenter, open-label study evaluating long-term safety, tolerability, and efficacy of monthly subcutaneous administration of fremanezumab for the…Ajovy (fremanezumab) | Teva Pharmaceutical Industries | Ongoing |
| Apr 12, 2019 | "a phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of erenumab in children (6 to < 12 years)…Aimovig | Amgen | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA